공시 • May 29
Positron Corporation Expands Market Presence with Sale of NeuSight Pet-CT Scanner Positron Corporation announced the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing in advanced cardiovascular diagnostics and interventional care. This latest sale highlights the growing demand for Positron's PET and PET-CT solutions, which combine cutting-edge technology with comprehensive clinical, technical and training support. Positron continues to deliver the most effective and cost-efficient imaging platform for nuclear cardiology and molecular imaging practices nationwide. The NeuSight PET- CT is engineered to elevate cardiac PET imaging through a unique combination of advanced technology, exceptional performance, and unmatched value. Internationally recognized, the system features a spacious 72 cm gantry for patient comfort and high-sensitivity acquisition that reduces radiation exposure for both patients and staff. With the smallest footprint and lightest weight in its class, NeuSight is ideal for all healthcare environments where space and efficiency matter. Offering both anatomic and functional imaging, it supports a wide range of studies--including cardiac, tumor, and neurological imaging -- making it a powerful tool for practices committed to delivering superior patient care. 공시 • Jan 29
Positron Corporation Announces Sales of Attrius Pet and Neusight Pet-Ct 64 Slice Nuclear Imaging Systems Positron Corporation announced sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices. The Attrius is a 2D quantitative dedicated PET scanner optimized for nuclear cardiology. The Attrius provides high-resolution images in tandem with robust blood flow data for analysis optimal for the latest in coronary flow reserve software, assisting the generation of accurate measurements of absolute blood flow and coronary flow reserve. The NeuSight PET-ct is designed to transform cardiac PET imaging by combining exceptional performance, advanced technology, and unmatched value. Renowned for its top-tier performance and international success, the NeuSight PET- CT stands out with its patient-centered design, featuring a spacious 72 cm gantry for enhanced comfort and high-sensitivity acquisition technology that minimizes radiation exposure for both patients and technicians. With the smallest footprint and lightest weight among PET-CT systems, it offers superior imaging capabilities while optimizing space utilization, making it an ideal solution for modern healthcare facilities. As a cost-effective and innovative system, the NeuSightPET-CT excels in both cardiology and oncology clinical studies. Its advanced data acquisition and identification technology enable faster and more precise scans, improving diagnostic accuracy. Offering both anatomic and functional imaging, the NeuSight Pet-CT supports a wide range of molecular imaging applications, including heart, tumor, and brain studies, showcasing its versatility and commitment to advancing medical diagnostics. 공시 • Jul 25
Positron Corporation Introduces New, Advanced Designed, Economically Priced PET-CT Positron Corporation announced to present its new NeuSight PET-CT 3D 64 slice scanner, available for US and North American Markets. The NeuSightPET-CT advanced technology sets a new standard in imaging and diagnostic precision, patient comfort, and operational efficiency for nuclear cardiology practices and hospitals. The NeuSight PET-CT was designed to revolutionize cardiac PET imaging, offering unparalleled value, empowering practices with cutting-edge technology at an unmatched price. The NeuSight PET-CT scanner is a highly acclaimed, top performing scanner, with installations throughout the world. The NeuSight PET-CT is an innovative, inexpensive PET-CT system making it ideal for both cardiology and oncology clinical studies having superior data acquisition, with identification technology for improved scanning speed and accuracy. The NeuSight PET-CT system provides anatomic and functional imaging with qualified designs and technology, serving multiple molecular imaging functions for heart, tumor, and brain imaging studies. NeuSight PET-CT’s detector modules are designed to interface with scintillating crystals for improved photoelectric conversion efficiency, high sensitivity, and temporal resolution. Proprietary IPIE technology improves spatial resolution and data accuracy. A key feature of NeuSight PET-CT incorporates clear honeycomb and patented asymmetrical light-guided technology delivering superior image clarity and resolution, essential for accurate cardiac diagnostics. Advanced clinical applications from 4D Gate capabilities for precise attenuation correction and fusion to optimized image fusion algorithms and quality control procedures, the system enables clinicians to achieve superior clinical outcomes with every scan. 공시 • Dec 21
Positron Corporation Announces Plans for Clinical Study of Its New “Affinity Pet-Ct 4D” Nuclear Imaging Device Positron Corporation announced the Company’s collaboration with Dr. Bober and Ochsner Health, the largest non-profit, academic healthcare system operating in Louisiana, for the clinical study of Positron’s new “Affinity PET-CT 4D” nuclear imaging device. The clinical study is sponsored by Positron and will be conducted by Dr. Robert Bober, Director of Molecular Imaging and Nuclear Cardiology of Ochsner Health. Dr. Bober has furnished a plan for the clinical study to an Institutional Review Board (IRB), which reviews and monitors biomedical research involving human subjects in accordance with FDA regulations. Performing such an extensive clinical study requires a comprehensive investigational plan, patient selection criteria, labeling, and monitoring with records and reports which adhere to Good Clinical Practices (GCP). Following the formalization of the plan with IRB and on-site installation the clinical study is expected to begin in mid-January with an estimated time of completion of three (3) weeks. The study will be performed at Ochsner Health’s New Orleans facility under the guidance of Dr. Bober. The study will provide empirical data necessary for proper representation of the system’s image quality, performance, and efficacy with cardiac PET imaging agents. Testing will encompass an extensive array of patients, comprising of a diverse range of ages, body habitus, and clinical indications. The results of the study and data received will be organized by Dr. Bober and disseminated as collateral for Positron’s Affinity PET-CT 4D marketing efforts. 